Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Technology | June 22, 2015

June 22, 2015 - The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug...

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
Feature | Antiplatelet and Anticoagulation Therapies | June 10, 2015

June 9, 2015 - AstraZeneca announced full results from the...

rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015
News | May 21, 2015

May 21, 2015 — Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI
Feature | Antiplatelet and Anticoagulation Therapies | May 18, 2015

May 18, 2015 — A risk assessment algorithm...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI
News | May 18, 2015

May 18, 2015 — Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI
Feature | May 15, 2015

May 15, 2015 — Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing...

News | May 14, 2015

May 14, 2015 — A new study reports that antiplatelet drug ...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed
Feature | May 06, 2015

May 6, 2015 — People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart...

News | May 01, 2015

One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called...

Brilinta, AstraZeneca, FDA, sNDA, PEGASUS-TIMI 54, new indication
News | April 30, 2015

April 30, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...

The Medicines Company, cangrelor, FDA advisory committee, approval
Feature | April 29, 2015

April 29, 2015 — The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and...

News | March 30, 2015

March 30, 2015 — The Medicines Company announced that the European Commission has granted marketing authorization...

ticagrelor, AstraZeneca, FDA, crushing, option
Technology | March 30, 2015

March 30, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new...

Overlay Init